Neurogene Inc. Files 8-K on Financials
Ticker: NGNE · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1404644
Sentiment: neutral
Topics: financial-reporting, company-update
TL;DR
Neurogene Inc. filed an 8-K on March 18, 2024, updating on financials and company status.
AI Summary
Neurogene Inc. filed an 8-K on March 18, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011. The company was formerly known as Neoleukin Therapeutics, Inc. and has undergone previous name changes.
Why It Matters
This filing provides an update on Neurogene Inc.'s operational and financial status, which is crucial information for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine filing providing basic company information and financial reporting, not indicating any immediate significant risks.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- March 18, 2024 (date) — Date of Report
- 535 W 24th Street, 5th Floor, New York, NY 10011 (location) — Principal executive offices
- Neoleukin Therapeutics, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Neurogene Inc.?
The primary purpose of this 8-K filing is to report on Neurogene Inc.'s results of operations and financial condition.
When was this 8-K report filed by Neurogene Inc.?
This 8-K report was filed on March 18, 2024.
What is the current business address for Neurogene Inc.'s principal executive offices?
Neurogene Inc.'s principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011.
What was Neurogene Inc. formerly known as?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc.
Under which state was Neurogene Inc. incorporated?
Neurogene Inc. was incorporated in Delaware.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-18 16:10:58
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
Filing Documents
- ngne-20240318.htm (8-K) — 26KB
- ngne_q4yereleasexexhibit991.htm (EX-99.1) — 66KB
- image_0.jpg (GRAPHIC) — 3KB
- 0001404644-24-000024.txt ( ) — 231KB
- ngne-20240318.xsd (EX-101.SCH) — 2KB
- ngne-20240318_lab.xml (EX-101.LAB) — 22KB
- ngne-20240318_pre.xml (EX-101.PRE) — 13KB
- ngne-20240318_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On March 18, 2024, Neurogene Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2023. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: March 18, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer